Table 1 Clinical-pathological characteristics of the study participants (N: 235)
Characteristics | Number (N) and percentage (%) |
|---|---|
Age (years) | N (%) |
Mean (SD) | 60.3 (13.4) |
Histology | |
 Intraductal carcinoma | 204 (86.8) |
 Lobular carcinoma | 14 (6.0) |
 Other | 9 (3.8) |
 Unknown | 8 (3.4) |
pT stage | |
 pT1 | 131 (55.7) |
 pT2 | 104 (44.3) |
pN stage | |
 pN0 | 141 (60.0) |
 pN1 | 83 (35.3) |
 Unknown | 11 (4.7) |
Grading | |
 1 | 16 (6.8) |
 2 | 126 (53.6) |
 3 | 64 (27.2) |
 Unknown | 29 (12.3) |
Estrogen receptor status | |
 Positive | 186 (79.1) |
 Negative | 49 (20.9) |
Progesterone receptor status | |
 Negative | 71 (30.2) |
 Positive | 164 (69.8) |
HER2 status | |
 Positive | 39 (16.6) |
 Negative | 196 (83.4) |
% Ki-67 | |
 ≤ 15 | 142 (60.4) |
 > 15 | 89 (37.9) |
 Unknown | 4 (1.7) |
Molecular subtype | |
 Triple-negative | 30 (12.8) |
 Luminal A | 118 (50.2) |
 Luminal B | 69 (29.3) |
 HER2-enriched | 18 (7.7) |